BioCentury
ARTICLE | Company News

Pfizer restructuring commercial operations

July 30, 2013 12:09 AM UTC

Pfizer Inc. (NYSE:PFE) on Monday said it plans to integrate its commercial operations for developed and emerging markets and internally separate the operations into three business segments starting in January. The pharma currently has two operating models in developed markets -- an innovative segment focused on patent protected products and a value segment focused on generics -- and has previously said it was evaluating whether its operating model in emerging markets should "more closely mirror" its model for developed markets. The pharma's model in emerging markets currently has a geographic focus.

Pfizer's three business segments will comprise two innovative segments for products with market exclusivity beyond 2015 -- one focused on inflammation and immunology, cardiovascular/metabolic, neuroscience and pain, rare diseases and women's/men's health, and the other focused on vaccines, oncology and consumer healthcare. The pharma's third value segment will focus on products that have lost or are expected to lose market exclusivity through 2015 in most major markets, as well as biosimilars and "established products" collaborations. ...